SEARCH

SEARCH BY CITATION

Figure S1. PDGFRα immunoreactivity using two different antibodies. (A) Negative control, No Primary antibody. (B) PDGFRα antibody used in study (R&D Systems). (C) PDGFRα antibody (new from Cell Signaling Technology). (D) Overlap of PDGFRα antibodies suggesting antibody used is specific for PDGFRα.

Figure S2. SK3 immunoreactivity using two different antibodies. (A) Negative control, No Primary antibody. (B) SK3 antibody used in study (Alomone Labs). (C) SK3 antibody (new from Millipore). Note that both antibodies are rabbit polyclonal. Used on adjacent sections.

Figure S3. Diabetic gastroparesis grouped with and without ICC loss. No difference in the number of PDGFRα immunoreactive cells amongst patients with or without ICC loss was seen.

Figure S4. Idiopathic gastroparesis grouped with and without ICC loss. No difference in the number of PDGFRα immunoreactive cells amongst patients with or without ICC loss was seen.

Table S1. Primary antibodies used.

Table S2. Detailed staining protocols for PDGFRα and SK3 immunoreactivity.

Table S3. Quantitative differences in PDGFRα-ir fibroblast-like cells in gastroparesis and controls.

FilenameFormatSizeDescription
NMO_1944_sm_FigS1.tif1420KSupporting info item
NMO_1944_sm_FigS2.tif655KSupporting info item
NMO_1944_sm_FigS3.tif88KSupporting info item
NMO_1944_sm_FigS4.tif97KSupporting info item
NMO_1944_sm_Supplementary-Figure-legends.doc35KSupporting info item
NMO_1944_sm_Supplementary-Figure-legends.docx13KSupporting info item
NMO_1944_sm_TableS1.docx14KSupporting info item
NMO_1944_sm_TableS2.docx13KSupporting info item
NMO_1944_sm_TableS3.docx11KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.